Columnist Dagmar Munn feels as if she's finding her voice again as she picks up her speech exercises, and then some.

Patient randomization is nearly complete in Medicinova’s Phase 2b/3 COMBAT-ALS trial testing MN-166 (ibudilast) for the ...

Answer ALS is backing a Louisiana collaboration aimed at using AI to accelerate drug discovery for ALS and other ...

AB Science's new Phase 3 trial of masitinib for ALS has been cleared to launch in certain European countries, as well as in ...

Columnist Kristin Neva shares what she feels has worked and not worked in terms of slowing her husband's ALS progression over 15 years.

The FDA approved an expanded access program for troculeucel, making the treatment available to patients outside clinical trials.

Caregivers can keep communication going for people living with ALS by using tools, patience, and clear language.

The ongoing EAP that is providing ALS patients with access to MN-166 (ibudilast) outside of a clinical trial is adding more ...

The ongoing EAP that is providing ALS patients with access to MN-166 (ibudilast) outside of a clinical trial is adding more sites.

AUT00201, an oral small molecule, reduced the loss of motor neurons and eased motor symptoms in a mouse model of ALS, a study ...

CB03-154 is a newer ALS therapy that's designed to open nerve cells' KCNQ2 and KCNQ3 potassium channels without affecting ...